Bayesian Capital Management’s Genomic Health, Inc. GHDX Stock Holding History

Bayesian Capital Management’s Portfolio GHDX Stock Details GHDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-9,758	Closed	-$684K	–	752
2019 Q1	$684K	Sell	9,758 -7,100	-42%	-$526K	0.13%	223
2018 Q4	$1.09M	Buy	16,858 +4,400	+35%	+$308K	0.22%	141
2018 Q3	$875K	Buy	+12,458	New	+$729K	0.14%	204

Other funds holding GHDX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bayesian Capital Management's GHDX Position: Q2 2019 in Review

Bayesian Capital Management sold out of Genomic Health, Inc. (GHDX) in Q2 2019, closing a stake of 9,758 shares — an estimated $684K sold.

Bayesian Capital Management first reported a position in GHDX in Q3 2018 and held it in 3 quarters. The position peaked at $1.09M in Q4 2018. 215 funds tracked by Wall St. Rank hold GHDX as of Q2 2019.

Bayesian Capital Management reported no remaining Genomic Health, Inc. position as of Q2 2019 after selling out during the quarter.
Bayesian Capital Management sold 9,758 Genomic Health, Inc. shares in Q2 2019, an estimated $684K.
Bayesian Capital Management first reported a position in Genomic Health, Inc. in Q3 2018 and held it in 3 quarters.
Bayesian Capital Management's Genomic Health, Inc. position peaked at $1.09M in Q4 2018.
215 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q2 2019.

Based on Bayesian Capital Management's 13F filing for Q2 2019, filed 13 Aug 2019.